Skip to main
LXRX
LXRX logo

Lexicon Pharmaceuticals (LXRX) Stock Forecast & Price Target

Lexicon Pharmaceuticals (LXRX) Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 20%
Buy 10%
Hold 50%
Sell 20%
Strong Sell 0%

Bulls say

Lexicon Pharmaceuticals Inc. has demonstrated a positive outlook primarily due to favorable topline results from the Phase 2b PROGRESS clinical trial for its drug candidate LX9211, which effectively treated diabetic peripheral neuropathic pain. The successful identification of an optimal 10 mg dose positions the company for future Phase 3 trials and signifies potential for enhanced market penetration in critical therapeutic areas such as heart failure and cardiometabolic disorders. Additionally, the strong partnership interest in pilavapadin underscores the significant addressable market, further contributing to an optimistic growth trajectory for the company.

Bears say

The analysis of Lexicon Pharmaceuticals Inc. indicates a negative outlook primarily due to disappointing results from their RELIEF DPN-1 trial, where the 20 mg dose failed to achieve statistical significance compared to placebo, raising concerns about its efficacy. Additionally, there are significant risks related to potential failed or inconclusive clinical trials and the company's ability to secure adequate funding for ongoing drug development, which could hinder future progress. Tolerability issues at higher doses and a higher dropout rate further complicate the outlook, potentially impacting investor confidence and future valuations.

Lexicon Pharmaceuticals (LXRX) has been analyzed by 10 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 10% recommend Buy, 50% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lexicon Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lexicon Pharmaceuticals (LXRX) Forecast

Analysts have given Lexicon Pharmaceuticals (LXRX) a Hold based on their latest research and market trends.

According to 10 analysts, Lexicon Pharmaceuticals (LXRX) has a Hold consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lexicon Pharmaceuticals (LXRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.